On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the trading session's close. They were highly encouraged by the specialized ...

ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP) reported a narrower-than-expected loss and revenue that surpassed analyst estimates for the fourth quarter of 2024, sending shares up 0.

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Reports Q4 revenue $35.69M. “With continued advancements across our commercial and clinical portfolio, CRISPR Therapeutics (CRSP) is poised to ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

We expect the company to start recording collaboration revenues ... of CRISPR Therapeutics have lost nearly 34% in the past year compared with the industry’s 14% decline, as seen in the chart ...

CRISPR Therapeutics AG (NASDAQ ... While recent revenue growth reached 19.31%, analysts anticipate a sales decline in the current year, highlighting the importance of monitoring the company's ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared ... the company is yet to record revenues from its sales. Also, a lack of pipeline updates ...